Clinical Trial Update: MK-3475 in Combination With Docetaxel vs Docetaxel Alone in Non-Small Cell Lung Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating MK-3475 (pembrolizumab) with docetaxel versus docetaxel alone in non-small cell lung cancer has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• MK-3475 (pembrolizumab)

Snippet

Sponsor: Instituto Nacional de Cancerologia de Mexico | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED | Results posted: 2020-12-14